Related Experiment Video

Updated: Apr 28, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

[Parallel pharmacological correction of myocardial dysfunction, cognitive and psychopathological disordres in

N Ia Dotsenko, S S Boev, I A Shekhunova

    Likars'Ka Sprava
    |June 10, 2014
    PubMed

    Insights

    This study found that Vazonat improves cardiac function in heart failure patients. Combining Vazonat with Adaptol further enhanced these benefits, reducing symptoms and improving mood.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Congestive heart failure (CHF) with reduced ejection fraction (left ventricular ejection fraction < 45%) and coronary artery disease presents significant management challenges.
    • Current therapies aim to improve hemodynamic indicators and congestive functions.

    Purpose of the Study:

    • To evaluate the efficacy of Vazonat, alone and in combination with Adaptol, as an adjunct to standard therapy for patients with CHF.
    • To assess the impact on cardio-hemodynamic indicators, congestive functions, and psychological symptoms.

    Main Methods:

    • A study involving 92 patients with CHF (NYHA class III-IV FC) and coronary artery disease.
    • Control group received basic therapy.
    • Group 1 received Vazonat intravenously (1000 mg/day for 15 days) followed by oral administration (250 mg 3 times/day for 1 month).
    • Group 2 received Vazonat and Adaptol (500 mg twice/day) following the same administration schedule.

    Main Results:

    • Vazonat addition to basic treatment showed additional benefits in improving cardio-hemodynamic indicators and congestive functions.
    • Combined Vazonat and Adaptol therapy resulted in more pronounced improvements in congestive functions.
    • The combination therapy led to a progressive reduction in distress and depression.

    Conclusions:

    • Vazonat is an effective adjunct therapy for improving cardiac function in CHF patients.
    • The combination of Vazonat and Adaptol offers superior benefits, addressing both cardiac and psychological aspects of the condition.

    More Related Videos

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    9.0K
    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017

    10.2K

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.7K
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    750
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    622
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    788
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    631
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    804